Externa
Externa is a platform technology company from the Church and Collins labs that combines synthetic biology, chemistry, and machine learning to bring the power of medicinal chemistry to protein therapeutics with synthetic amino acids. These new-to-nature amino acids give proteins new capabilities, such as irreversible binding, longer stability, or pH-dependent activity.
PathCision Medicine, Inc
PathCision Medicine is harnessing tissue pathology insights to develop new targeted therapies. Built using a translational lens with a multi-omics approach, its proprietary discovery platform uncovers novel therapeutic avenues previously unavailable to patients with complex diseases. PathCision’s leading program is focused on developing a biologic modality for metastasis-selective delivery for multiple indications.
-
Shana Wang
CEO
Tezcat Biosciences, Inc
Tezcat Biosciences is developing a portfolio of protein-drug conjugates to provide therapeutic options for patients harboring mutant RAS cancers. Tezcat’s current portfolio consists of conjugates combining its proprietary protein carrier with established drug payloads. To-date, Tezcat’s drug development has been supported by academic collaborations and government awards.
-
Alexander Efron, MBA
Business Advisor
General Biologics, Inc
General Biologics is a protein engineering company with a platform technology that targets therapeutic proteins to red blood cell precursors and mature red blood cells. This enhances plasma half-life and shields therapeutic proteins from the immune system, and when needed, will activate red blood cell production without side effects.
-
Jeffrey C. Way
President & Chief Executive Officer
-
R. Rogers Yocum
Chief Financial Officer
-
Pamela A. Silver
Scientific Advisor
Ilios Therapeutics, Inc
Ilios Therapeutics utilizes a proprietary modular chemistry platform to develop first-in-class multi-valent small molecules modulating multiple complementary mechanisms involved in neurodegenerative diseases.
-
Dr. Fares Nigim
Founder
-
Luca Giani
Founder & CEO
InGel Therapeutics
InGel Therapeutics is developing innovative cell-based therapy to bring back light to patients who suffer from all forms of retinal degeneration. Our lead program, IGT001, is a mutation-agnostic approach to Retinitis Pigmentosa, with future expansion opportunities including dry AMD and Glaucoma.
-
Pierre Dromel
Co-founder & Chief Executive Officer
-
Deepti Singh
Co-founder & Chief Scientific Officer
-
Patrick Jiang
Co-founder & Chief Business Officer
-
Michael Young
Co-founder & Chairman of SAB
RiverWalk Therapeutics
Riverwalk Therapeutics is a preclinical drug development company developing adenosine A2 receptor inhibitors for treating metastatic cancer. Our lead molecule, RW-108, has demonstrated significant potency reducing primary tumors (70%), extending lifespan (>40%), reducing bone metastases (98%), and depleting circulating tumor cells in the blood (78%) and bone marrow (98%).
-
Johanna Vincze Webb
President
-
Jean X. Jiang
Chief Science Officer & Chairman of the Board
Samba BioLogics
Samba BioLogics, Inc. is a preclinical stage biotechnology company based in Vermont. It produces breakthrough agonist biologics that preserve tissue and improve repair after ischemic injury. Our patent portfolio includes “Cell-Kro,” a biologic drug that promotes engraftment of transplanted progenitor cells, and “VasaPlex,” a biologic that rescues jeopardized cardiac tissue after myocardial infarction.
-
Dylan Ratigan
Co-founder & Chief Executive Officer
-
Jeffrey Spees
Co-founder & Chief Scientific Officer
-
Benjamin Liebman
Director, Drug Development & Innovation
-
Wolfgang Dostmann
Director of Pharmacology & Medicinal Chemistry
AdductNE, LLC
AdductNE is a radiopharmaceutical company spun-out from the University of Nebraska Medical Center (UNMC) in 2019. AdductNE is dedicated to developing targeted imaging and therapeutic agents for cancer.
-
Jered Christopher Garrison, PhD
President & Chief Scientific Officer
-
Shana Garrison, PhD
Chief Financial Officer
HDAX Therapeutics
HDAX Therapeutics is developing a targeted therapeutics platform for the safe and efficacious treatment of HDAC-driven pathologies such as neuropathies and cancers by rationally designing therapies to overcome common drug challenges including weak binding, off-target toxicities, and poor pharmacokinetic profiles.
-
Nabanita Nawar, PhD
Chief Executive Officer
-
Pimyupa Manaswiyoungkul, PhD
Chief Operations Officer
-
Olasunkanmi Olaoye, PhD
Vice President Drug Discovery
-
Elvin de Araujo, PhD
Chief Innovation Officer
-
Patrick Gunning, PhD
Scientific Advisor
Hybridex Biosciences
Hybridex Biosciences is an early-stage biotech company aiming to enable the next-generation of safe gene editing. Using its tunable antisense nucleic acid platform, developed in labs at Yale University, Hybridex aims to improve the safety and control of CRISPR-based systems to realize the full potential of gene editing therapeutics.
-
Jem Atillasoy, MD
Candidate, Co-founder
-
Nicholas Economos, MD/PhD
Candidate, Co-founder
Jenthera Therapeutics, Inc
Jenthera Therapeutics is a preclinical biotechnology company leveraging a novel non-viral, non-lipid CRISPR platform for the development of groundbreaking therapeutics. The platform presents tissue-specific delivery, built-in safety, and advanced gene correction capabilities, proposing to unlock new realms of therapeutic possibilities and allow for the development of complex multi-loci corrective gene therapies.
-
Dr. Philip Roche
Chief Executive Officer, Chief Scientific Officer
-
Laurent D. Ziri, CPA-CA
Chief Operations Officer
-
Sandra Azoulay, CPA-CA
Chief Financial Officer, Communications